High Throughput Screening (HTS) is a drug-discovery process widely used in the pharmaceutical industry. It leverages automation to quickly assay the biological or biochemical activity of a large number of drug-like compounds. It is a useful for discovering ligands for receptors, enzymes, ion-channels or other pharmacological targets, or pharmacologically profiling a cellular or biochemical pathway of interest. Typically, HTS assays are performed in “automation-friendly” microtiter plates of 96, 384 or 1536 well format. To this end, the Lead Identification Department at Scripps Florida has set-up a state-of-the art HTS operation to support HTS efforts. This department has both HTS and compound management automation, and expertise in adapting biological and biochemical bench-top assays into high-throughput screens. This centralized uHTS laboratory supports drug discovery efforts, as a collaborative program that allows scientists access to Scripps facilities. The anchors of the department are two Kalypsys/GNF robotic platforms; one to support 1536-well based ultra-HTS (uHTS) efforts and the other to manage Scripps’ small-molecule compound collection. Additionally, this department has the laboratory equipment & expertise to facilitate HTS assay implementation and downstream lead discovery efforts. We also manage Scripps extensive (> 650,000 member) drug screening compound collection for HTS, Medicinal Chemistry and Pharmacology efforts. We provide assistance for biomedical researchers with their development of HTS compatible assays. We engage in the exploration and implementation of novel technologies for the advancement of HTS.
Scripps Florida - Molecular Screening Center has not received any reviews.
Scripps Florida - Molecular Screening Center has not received any endorsements.